CVRx Reports Fourth Quarter and Full Year 2024 Financial and Operating ResultsMINNEAPOLIS, Feb. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the fourth quarter and full year of 2024.
CVRx Appoints Industry Veteran Kevin Hykes to Board of DirectorsMINNEAPOLIS, Dec. 20, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (
NASDAQCVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Kevin Hykes will join its Board of Directors effective December 21, 2022.
CVRx Launches new Barostim NEO2™ Implantable Pulse GeneratorThe new Barostim NEO2 Implantable Pulse Generator (IPG) launches in the U.S., improving the patient experience while on therapy and simplifying the implant procedure for physicians
